- Home
- CJET vs SLXN Comparison
CJET vs SLXN Comparison
Compare CJET & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJET
- SLXN
- Stock Information
- Founded
- CJET 2009
- SLXN 2008
- Country
- CJET China
- SLXN Israel
- Employees
- CJET N/A
- SLXN N/A
- Industry
- CJET Auto Manufacturing
- SLXN
- Sector
- CJET Consumer Discretionary
- SLXN
- Exchange
- CJET Nasdaq
- SLXN NYSE
- Market Cap
- CJET 8.3M
- SLXN 6.9M
- IPO Year
- CJET N/A
- SLXN N/A
- Fundamental
- Price
- CJET $1.96
- SLXN $0.93
- Analyst Decision
- CJET
- SLXN Strong Buy
- Analyst Count
- CJET 0
- SLXN 1
- Target Price
- CJET N/A
- SLXN $5.00
- AVG Volume (30 Days)
- CJET 185.7K
- SLXN 3.6M
- Earning Date
- CJET 05-06-2025
- SLXN 05-21-2025
- Dividend Yield
- CJET N/A
- SLXN N/A
- EPS Growth
- CJET N/A
- SLXN N/A
- EPS
- CJET N/A
- SLXN N/A
- Revenue
- CJET $10,275,000.00
- SLXN N/A
- Revenue This Year
- CJET N/A
- SLXN N/A
- Revenue Next Year
- CJET N/A
- SLXN N/A
- P/E Ratio
- CJET N/A
- SLXN N/A
- Revenue Growth
- CJET 31.31
- SLXN N/A
- 52 Week Low
- CJET $1.09
- SLXN $0.21
- 52 Week High
- CJET $23.94
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- CJET 59.07
- SLXN N/A
- Support Level
- CJET $1.68
- SLXN N/A
- Resistance Level
- CJET $2.00
- SLXN N/A
- Average True Range (ATR)
- CJET 0.21
- SLXN 0.00
- MACD
- CJET 0.00
- SLXN 0.00
- Stochastic Oscillator
- CJET 78.25
- SLXN 0.00
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the research and development, production and sales of new energy vehicles. New energy vehicles refer to plug-in electric vehicles including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.